InvestorsHub Logo
Followers 21
Posts 3570
Boards Moderated 0
Alias Born 12/18/2019

Re: B52T38 post# 203070

Tuesday, 02/08/2022 11:24:22 PM

Tuesday, February 08, 2022 11:24:22 PM

Post# of 233049
The partnership fantasy -- Another NP fiction. HNP had hyped partnerships regularly over the last three years and other than Vyera, the worst U.S. drug company (paid only $5 mil upfront) and American Regent (paid nothing) they never delivered. What indication would there be? NASH 350 mg was mediocre at best (16-20% fat reduction vs. 48% for Madrigal). Nobody commits serious money for mediocre drugs. mTNBC data was so muddled that no one knows what the REAL data was. No BTD, and virtually unreadable data release -- so bad, the SEC and the DOJ expanded their investigation to cover the mTNBC communication.

Np potential partner wants to potentially partner with a bankruptcy judge. Then there is all the legal problems that could affect partner too. And the data hasn't gone through an independent peer-review. Cytodyn has a poor reputation for credibility of their data -- FDA Statement reprimanding CYDY for their CoV data, mTNBC SEC/DOJ investigation plus the absence of peer review.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News